Skip to content

CJC-1295 (with DAC)

Tags: GHRH analogue, DAC, Long-acting, Growth Hormone

Quick Summary

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting, albumin-binding GHRH analogue engineered for extended duration (half-life ~6–8 days), providing sustained GH and IGF-1 elevation with weekly dosing.

Overview

CJC-1295 with DAC is engineered to prolong circulation time via albumin binding, producing continuous GHRH receptor stimulation rather than the short GH pulses of natural physiology.

Key Benefits

  • Weekly dosing convenience
  • Sustained GH/IGF-1 elevation for days after a single injection
  • Noticeable body-composition and recovery effects at clinical doses

Mechanism of Action

The DAC moiety increases plasma albumin binding, extending circulation time and providing continuous GHRH receptor stimulation.

Molecular Information

  • Weight: 3,647.28 Da
  • Length: 30 amino acids
  • Type: GHRH analog with DAC
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

Note: DAC extends half-life to ~6–8 days, allowing weekly administration.

Research Indications

  • Sustained growth hormone elevation (primary indication)
  • IGF-1 optimization for clinical/research uses
  • Body-composition improvements and recovery support

Research Protocols

Goal Dose Frequency Route
Conservative Anti-Aging 1 mg Once weekly Subcutaneous
Standard Protocol 2 mg Once weekly Subcutaneous
Split Dosing 1 mg Twice weekly (Mon/Thu) Subcutaneous
Loading Protocol 2 mg first week, then 1 mg Weekly Subcutaneous

Timing: Injection timing is flexible due to long half-life; many prefer morning dosing to monitor side effects.

Interactions

Compatible / Complementary

  • Sermorelin — Use caution / complementary in some protocols

Monitor

  • Ipamorelin — Use caution
  • GHRP-6 — Use caution
  • Sermorelin — Use caution

Avoid

  • CJC-1295 (without DAC) — Avoid combination
  • MK-677 (Ibutamoren) — Avoid combination
  • Tesamorelin — Avoid combination
  • HGH — Avoid combination

How to Reconstitute (practical notes)

  1. Clean both vial tops with alcohol and allow to dry.
  2. Use bacteriostatic water (BAC) — sterile technique is essential.
  3. For 2 mg vial: add 1 mL BAC water (creates ~2 mg/mL concentration).
  4. For 5 mg vial: add 2.5 mL BAC water (creates ~2 mg/mL concentration).
  5. Inject water slowly down vial wall to reduce foaming — DAC peptides foam easily.
  6. Let sit ~5 minutes, then gently roll to mix.
  7. Label with date and concentration and refrigerate.

Quality Indicators

Positive Signs

  • DAC peptides with COA showing >98% purity
  • Proper labeling stating "with DAC" and clear vendor COA

Warning Signs

  • Impurities on COA or missing DAC labeling
  • Excessive foaming that does not settle or cloudy solution

What to Expect

  • Week 1: possible water retention, improved sleep, increased appetite
  • Week 2–3: recovery improvements, some report joint discomfort
  • Week 4–6: visible body-composition changes and increased vascularity
  • Week 6–8: continued benefits; monitor for desensitization signs
  • Post-cycle: IGF-1 typically declines to baseline within 2–3 weeks

Side Effects & Safety

  • Higher side-effect incidence compared with pulsatile protocols
  • Common: water retention, joint pain, carpal tunnel symptoms
  • Monitor for signs of excessive GH (acral growth)
  • Not recommended for people with active cancer or uncontrolled diabetes
  • May worsen sleep apnea in predisposed individuals
  • Regular IGF-1 monitoring advised for extended use

References

Prolonged Growth Hormone Elevation with CJC-1295 DAC (2006)

  • Human | 30-60 mcg/kg | Single injection | 12 subjects

Demonstrated sustained GH and IGF-1 elevation for 6-10 days following a single injection, with peak levels 2-4x baseline maintained throughout.

Dose-Response Relationship of CJC-1295 DAC (2008)

  • Human | Multiple doses | 90 days | 48 subjects

Established optimal dosing at 1-2 mg weekly, showing dose-dependent IGF-1 increases but also higher side effect incidence at doses above 2 mg.

Long-term Effects on GH/IGF-1 Axis (2012)

  • Animal model | 6 months | Weekly dosing

Chronic administration led to sustained IGF-1 elevation but some evidence of reduced GH pulse amplitude, suggesting partial desensitization.